"Risperidone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
| Descriptor ID |
D018967
|
| MeSH Number(s) |
D03.383.742.698.685
|
| Concept/Terms |
R-64,766- R-64,766
- R 64,766
- R64,766
- R-64766
- R 64766
- R64766
|
Below are MeSH descriptors whose meaning is more general than "Risperidone".
Below are MeSH descriptors whose meaning is more specific than "Risperidone".
This graph shows the total number of publications written about "Risperidone" by people in this website by year, and whether "Risperidone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 2 | 0 | 2 |
| 2006 | 1 | 1 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 5 | 1 | 6 |
| 2010 | 2 | 0 | 2 |
| 2011 | 3 | 0 | 3 |
| 2012 | 1 | 3 | 4 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 1 | 3 |
| 2015 | 6 | 0 | 6 |
| 2016 | 1 | 0 | 1 |
| 2017 | 3 | 4 | 7 |
| 2018 | 2 | 2 | 4 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Risperidone" by people in Profiles.
-
New-Onset Psychosis in the Context of COVID-19 Infection: An Illustrative Case and Literature Review. J Acad Consult Liaison Psychiatry. 2023 Jul-Aug; 64(4):383-391.
-
A Transcriptome-Based Drug Discovery Paradigm for Neurodevelopmental Disorders. Ann Neurol. 2021 02; 89(2):199-211.
-
The effect of minocycline on amelioration of cognitive deficits and pro-inflammatory cytokines levels in patients with schizophrenia. Schizophr Res. 2019 10; 212:92-98.
-
Selective Serotonin Reuptake Inhibitors Reduce Longitudinal Growth in Risperidone-Treated Boys. J Pediatr. 2018 10; 201:245-251.
-
Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment. Nat Commun. 2018 06 11; 9(1):2265.
-
Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res. 2018 05 19; 20(1):42.
-
Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels. Prog Neuropsychopharmacol Biol Psychiatry. 2018 07 13; 85:69-76.
-
Neuroleptic Malignant Syndrome After Early Administration of Risperidone Long-Acting Injection. Prim Care Companion CNS Disord. 2017 Nov 30; 19(6).
-
Calcium and Vitamin D Supplementation in Boys with Risperidone-Induced Hyperprolactinemia: A Randomized, Placebo-Controlled Pilot Study. J Child Adolesc Psychopharmacol. 2018 03; 28(2):145-150.
-
CHRNA7 Deletions are Enriched in Risperidone-Treated Children and Adolescents. J Child Adolesc Psychopharmacol. 2017 Dec; 27(10):908-915.